Validation of Interobserver Agreement in Lung Cancer Assessment: Hematoxylin-Eosin Diagnostic Reproducibility for Non–Small Cell Lung Cancer: The 2004 World Health Organization Classification and Therapeutically Relevant Subsets

Abstract

Context Precise subtype diagnosis of non–small cell lung carcinoma is increasingly relevant, based on the availability of subtype-specific therapies, such as bevacizumab and pemetrexed, and based on the subtype-specific prevalence of activating epidermal growth factor receptor mutations. Objectives To establish a baseline measure of inter-observer reproducibility for non–small cell lung carcinoma diagnoses with hematoxylin-eosin for the current 2004 World Health Organization classification, to estimate interobserver reproducibility for the therapeutically relevant squamous/nonsquamous subsets, and to examine characteristics that improve interobserver reproducibility. Design Primary, resected lung cancer specimens were converted to digital (virtual) slides. Based on a single hematoxylin-eosin virtual slide, pathologists were asked to assign a diagnosis using the 2004 World Health Organization classification. Kappa statistics were calculated for each pathologist-pair for each slide and were summarized by classification scheme, pulmonary pathology expertise, diagnostic confidence, and neoplastic grade. Results The 12 pulmonary pathology experts and the 12 community pathologists each independently diagnosed 48 to 96 single hematoxylin-eosin digital slides derived from 96 cases of non–small cell lung carcinoma resection. Overall agreement improved with simplification from the comprehensive 44 World Health Organization diagnoses (κ = 0.25) to their 10 major header subtypes (κ = 0.48) and improved again with simplification into the therapeutically relevant squamous/nonsquamous dichotomy (κ = 0.55). Multivariate analysis showed that higher diagnostic agreement was associated with better differentiation, better slide quality, higher diagnostic confidence, similar years of pathology experience, and pulmonary pathology expertise. Conclusions These data define the baseline diagnostic agreement for hematoxylin-eosin diagnosis of non–small cell lung carcinoma, allowing future studies to test for improved diagnostic agreement with reflex ancillary tests.

Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin

“…Upon re-review of the frozen or formalin fixed sections, 11/28 lung squamous samples that cluster with the C1-LUAD-enriched group did not have squamous features and were reclassified as lung adenocarcinoma (Travis et al, 2011). NSCLCs are often difficult to classify based on histology alone (Grilley-Olson et al, 2013). That difficulty poses an important clinical challenge since histology is used to guide the selection of chemotherapy (Scagliotti et al, 2008) and to select patients for further mutational analysis (e.g., EGFR mutation and ALK fusion testing in non-squamous NSCLC).…”

Omics Profiling in Precision Oncology

“…However, these evaluations can be subjective (30,31) and the results may not capture all of the clinically relevant interindividual differences (32).…”

Drinking Not Drowning: How to Deal With the Deluge of Potential Predictive Biomarker Approaches in Non–Small-Cell Lung Cancer

“…Previous reports have suggested very low k-values for agreement between pathologists on whether an NSCLC exhibits squamous histology. 5 Although such studies were conducted before routine immunohistochemical support of the various histologic diagnoses was implemented, even modern histologic diagnoses still are not always set in stone. In support, the College of American Pathologists and others have deliberately included wording in their guidelines to loosen the restrictions on molecular testing from just adenocarcinoma when mixed histology with some component of adenocarcinoma exists or when the specimen is small and the histology may be less accurately ascribed.…”